Asiantuntijamme ovat kirjoittaneet, osallistuneet ja antaneet näkemystä satoihin julkaisuihin.
Soini E. Kustannusvaikuttavuustiedon tuottamisen rooli, haasteet ja mahdollisuudet nyt ja tulevaisuudessa. KWRC Seminar. Oct 22, 2012.
Soini E. Follikulaarisen lymfooman sekventiaalisen hoidon kustannusvaikuttavuus. BESTPRACTICE ONKOLOGIA / HEMATOLOGIA Lääketieteen asiantuntijoiden ammattilehti 2012;1(2):28-31.
Ainutlaatuinen kokonaisuus – Lääketutkimuksen kehittäjät. Lääketeollisuus ry:n ilmoitusliite Kauppalehti Nov 21, 2012. Tulevaisuuden lääkkeet, p. 3. Yksi haastatelluista: Soini, E.
Fimean suositus lääkkeiden hoidollisen ja taloudellisen arvon arvioinnista (Fimea recommendation for the assessment of the therapeutic and economic value of pharmaceuticals). Fimea kehittää, arvioi ja informoi -julkaisusarja 2/2012 (Serial Publication Fimea Develops, Assesses and Informs 2/2012). Projektiryhmän jäsen / project team member: Martikainen, J.
Asseburg C, Soini E, et al. Cost-effectiveness and budget impact of certolizumab pegol against a mix of treatments in an outcomes-based risk-sharing scheme in Finland. Value Health 2012;15(7):A454.
Martikainen J, Soini E, et al. Economic impact of 13-valent pneumococcal conjugate vaccine (PCV13) in persons over 50 years of age with underlying chronic medical conditions in Finland. Value Health 2012;15(7):A388-9.
Soini E, Mäkirinne-Kallio N, Martikainen J et al. Estimation of quality-adjusted survival with mild obstructive sleep apnoea and six quality of life (QoL) assessments: Comparison between trapezoid rule, cross-sectional and mixed model estimates. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:158.
Soini E, Leussu M, Hallinen T. Administration costs of intravenous biologic drugs for rheumatoid arthritis: Discrepancy between list cost prices and published costs. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:223.
Soini EJ, Martikainen JA et al. Comparison of EQ-5D- and 15D-based quality-adjusted life-years (QALY) in patients with mild obstructive sleep apnoea (MOSA) using mixed modelling: Measurement tool and tariff matter. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:159.
Asseburg C. Uncertainty in computer simulation models. Economics, Modelling and Diabetes: The Sixth Mt Hood Challenge. Baltimore, USA, Jun 7-8, 2012.
Hallinen T, Soini E, et al. Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland. Annals of the Rheumatic Diseases 2013;71(Suppl3):258-9. Poster presented at the Annual European Congress of Rheumatology (EULAR) 2012, Berlin.
Manca A, Asseburg C, et al. The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS). Value Health 2012;15(1):22-31.
Hallinen T, Soini E, et al. Dabigatraanin kustannusvaikuttavuus eteisvärinäpotilaiden aivohalvausten ehkäisyssä. Dosis 2012;28:130-44.
Hallinen T, Soini E, et al. Cost-effectiveness of insulin glargine compared to other long-acting basal insulins in the treatment of Finnish type 1 and type 2 diabetes patients based on individual studies. Dosis 2012;28:145-64.
Peura PK, Martikainen JA, et al. Sponsorship-Related Outcome Selection Bias in Published Economic Studies of Triptans: Systematic Review. Med Decis Making 2012;32(2):237-45.
Cummins E, Asseburg C, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ 2012;13(6):801-9.
Soini E, et al. Contingent Valuation of Eight New Treatments: What is the Clinician’s and Politician’s Willingness to Pay? The Open Complementary Medicine Journal 2012;4:1-11.
Soini E, Martikainen JA, et al. Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma. Clin Ther 2012;34(4):915-25.
Asseburg C, et al. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after switch to risperidone long-acting injection. Schizophr Res Treatment 2012; 2012: 791468.
Soini E, Hallinen TA, et al. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ 2012;15(2):340-51.
Martikainen J, Asseburg C, et al. Triptaanien kustannusvaikuttavuus akuutin migreenikohtauksen hoidossa. Lääkealan turvallisuus- ja kehittämiskeskus Fimea. Fimea kehittää, arvioi ja informoi –julkaisusarja 1/2011.
GAO. Value in Health Care. Key Information for Policymakers to Assess Efforts to Improve Quality While Reducing Costs. Washington: United States Government Accountability Office’s Report to Congressional Requesters, 2011. One of the responders: Soini, E.
Soini E. Harvinaissairauksien taloudellinen arviointi: mitä päätöksien tueksi tulisi tuottaa? Harvinaiset Sairaudet -lehti 2011;1:26-31.
Peura P, Turunen J, Purmonen T, Happonen P, Martikainen J. Mitä lääkehoitojen kustannusvaikuttavuus tarkoittaa? Sic! 2/2011
Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care -a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 2012;7(8):e42003.
Hallinen T, Soini E, et al. Differential use of extended and immediate release quetiapine: A retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. BMJ Open 2012;2(4):e000915.
Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. Int J Technol Assess Health Care 2012;28(4):382-9.
Willis M, Asseburg C, He J. Validation of Economic Simulation Models Using Clinical Trial Results: Experiences from Type 2 Diabetes Mellitus (T2DM). iHEA 2011. Podium. J Med Econ 2013;16(8):1007-21.
Willis M, Neslusan C, Asseburg C, et al. Initial HbA1c and HbA1c Lowering: Implications for Model-Based Economic Evaluations in Type 2 Diabetes Mellitus (T2DM). American Diabetes Association (ADA) meeting 2011. Podium.
Soini E, Martikainen J, et al. Cost-effectiveness of first-line rituximab maintenance treatment for follicular lymphoma. Haematologica 2011;96(s2):402. Poster at the Annual Congress of European Hematology Association (EHA 2011).